A Prospective, Multi-center Clinical Study to Establish Multi-Cancer Early Detection Platform through the Analysis of Whole Genome Sequencing of Circulating DNA in Cancer Patients and Healthy Volunteers
- Conditions
- Not Applicable
Recruitment & Eligibility
- Status
- Recruiting
- Sex
- All
- Target Recruitment
- 4000
Subjects prior to the start of treatment for stages 1 to 4 of various solid carcinomas or healthy adults who have scheduled a cancer medical examination
- Men and women over 19 years of age
- Subjects and healthy adults who agree to collect and analyze clinical information and human-derived materials for research purposes, and agree to store residual blood samples and use them for secondary research purposes
- Subjects who can donate blood without harming their health
- Subjects who understand and voluntarily agree to this study
- Subjects under the age of 19
- Vulnerable subjects with mental retardation or severe psychiatric conditions
- Subjects who are unable to participate in the study due to other reasons as determined by the researcher
- Subjects with a history of HIV, HTLV, and Syphilis infection
- Subjects diagnosed with primary unknown cancer or multiple cancers
- Subjects diagnosed with other malignant tumor within 5 years(except for non-melanoma skin cancer treated for cure, in-situ disease treated for cure, thyroid cancer, or intraepithelial carcinoma of the cervix)
Study & Design
- Study Type
- Observational Study
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Developing an analysis platform that can be used for early screening of some cancers
- Secondary Outcome Measures
Name Time Method Establishing a whole-genome sequencing(circulating DNA in blood) and clinical information database from 1,500 cancer subjects and 500 healthy adults